Report Overview

The Australian Sanfillipo Syndrome Therapeutics Market size stood at around USD XX billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Mucopolysaccaridosis III (MPS III) is a rare genetic condition that causes fatal brain damage. It is also known as Sanfilippo syndrome and is a type of childhood dementia. MPS III is caused by a lack of an enzyme that normally breaks down and recycles a large, complex sugar molecule called heparan sulphate. This heparan sulphate accumulates and causes damage to the cells of the central nervous system, including the brain. Sanfilippo belongs to a group of disorders known as the Mucopolysaccharidoses (MPS), which are part of a larger group of disorders known as lysosomal storage disorders. Children with MPS III usually appear healthy at birth, but developmental delay is usually evident by age 2-5 years. Mental and motor development peak by 3-6 years of age, after which intellectual decline usually occurs. Behavioral problems such as hyperactivity and irritability may become obvious earlier. Severe behavioral disturbance is a very common feature of Sanfilippo syndrome, and one of the more difficult aspects of the disorder to manage.

Sanfilippo is considered a rare disease: 1 in 70,000 children are born with the inherited condition. There are between 75 and 100 children living with Sanfilippo in Australia.



Market Drivers

The growing necessity for advanced therapeutics will impel companies to launch novel therapies, which in turn, will boost the Sanfillipo Syndrome (MPS III) Therapeutics market growth in the forthcoming years. Moreover, the growing unmet clinical needs of patients along with better treatment outcomes, financial incentives for orphan drug development to recover R&D costs, success for the drugs in pipeline with faster market access, high burden of rare diseases, favorable regulations for orphan products development will spur demand for Mucopolysaccharidosis Therapeutics market during the forecast period. Moreover, increasing acquisitions and deals between key players will bolster healthy growth of the market. High Treatment Costs, Lack of treatment options & lack of awareness will continue to hamper market.